Search - tctmd.com

Displaying 121 - 140 of 151

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2018

Shelley Wood

March 01, 2018

News Daily News

TCTMD’s Top 10 Most Popular Stories for December 2017

Shelley Wood

December 28, 2017

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Shelley Wood

December 26, 2017

News Conference News TCT 2017

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

Todd Neale

November 09, 2017

News Conference News TCT 2017

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

Todd Neale

November 08, 2017

News Conference News TCT 2017

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Michael O'Riordan

October 31, 2017

Podcast

Episode 18: Top News of TCT 2016 Plus Anticoagulation in A-fib Patients

October 11, 2017

News Conference News PCR London Valves 2017

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Shelley Wood

September 27, 2017

News Daily News

Permanent Pacemakers Post-TAVR Don’t Increase Adverse Event Risk: Meta-analysis

Ashley Lyles

August 08, 2017

Presentation SCAI 2017

Results From The BRAVO 3 Randomized Trial

Presenter: Usman Baber

May 15, 2017

News Conference News SCAI 2017

New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke

L.A. McKeown

May 12, 2017

Presentation SWVS 2017

Cases: The Good, The Bad and The Ugly

Presenter: Michael J. Reardon

May 07, 2017

News Conference News ACC 2017

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

L.A. McKeown

March 21, 2017

News Daily News

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

Todd Neale

March 14, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Conference News CRT 2017

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Michael O'Riordan

February 22, 2017

News Conference News CRT 2017

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

Michael O'Riordan

February 20, 2017

News Features

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Michael O'Riordan

January 24, 2017

News Daily News

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Michael O'Riordan

January 03, 2017

Presentation

Apixaban in Patients With Atrial Fibrillation After TAVR

Presenter: J. Seeger

January 03, 2017

Advertisement

TCTMD’s Top 10 Most Popular Stories for February 2018

TCTMD’s Top 10 Most Popular Stories for December 2017

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

Experts Debate: Should Cerebral Protection Be Used for All TAVRs?

A-fib Signals Worse Prognosis After Aortic Valve Replacement in Intermediate-Risk Patients

One in Six Patients With LBBB Post-TAVR Develop Atrioventricular Block

Episode 18: Top News of TCT 2016 Plus Anticoagulation in A-fib Patients

Pacemakers and Paravalvular Leak With Lotus: Updates From REPRISE III

Permanent Pacemakers Post-TAVR Don’t Increase Adverse Event Risk: Meta-analysis

Results From The BRAVO 3 Randomized Trial

New-Onset A-fib After TAVR Linked to Increased Risk of Early Stroke

Cases: The Good, The Bad and The Ugly

Add-on LAA Occlusion in Cardiac Surgery Cuts Thromboembolism Risk in A-fib Patients

NOACs Seem to Perform Just Fine in Patients With A-fib and Most Types of Valvular Disease

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Lotus TAVR Device With Depth Guard Reduces Risk of Pacemaker Implantation

Higher Mortality Among TAVR Patients With Atrial Fibrillation Treated With Triple Therapy

The Prickly Problem of Permanent Pacing After TAVR: One Hospital Pitches a Protocol

Best Anticoagulant in the TAVR Patient With A-fib? Small Study Makes Case for Apixaban

Apixaban in Patients With Atrial Fibrillation After TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content